

University of Texas Health Science Center at San Antonio
Institutional Biosafety Committee (IBC)
Microsoft Teams MINUTES OF MEETING
February 17, 2026

Members attending the meeting: Bieniek, Kevin; Burgin, Tiffani; Chatterjee, Bandana; Chen, Ching-Kang Jason; Chen, Chun-Liang; Dell, Shelbie; Ginsburg, Brett; Gould, Georgianna; Kautz, Tiffany; Prewit, Egle; Salamango, Daniel; Shio, Yuzuru; Vogel, Kristine; Wiederhold, Nathan; Xiang, Yan; Yeh, Chih-Ko; Bloodworth, Rebecca; Macias, Dorothy (alternate for Cerecero, Jennifer - voting)

Guests Present: Rincon, Erica; Melendez, Griselda; Barlett, Emily.

Absent members: Cerecero, Jennifer; Gauduin, Marie Claire; Martinez-Sobrido, Luis; Mishra, Bibhuti; Paukert, Martin.

1. Panel Chair Announcement

The meeting was called to order at 11:01 a.m. by the IBC Chair, Dr. Yan Xiang.

2. Confidentiality of Panel Proceedings and Conflict of Interest

The members of the panel and the persons employed by the panel shall maintain the confidentiality of the panel's proceedings unless such information is already made available to the public. The Parties shall maintain the confidentiality of the panel's hearings, deliberations, and initial report, and all written submissions to, and communications with, the panel.

Board Members will be reminded of their responsibility to declare any conflicts of interest prior to the discussion of an agenda item. Members will be reminded that in the event they have a conflict of interest (e.g. a member of the research team or is supervised by a member of the research team), the Member with a conflict may be in the meeting room to provide information requested by the IBC but will be asked to leave the meeting room before the final discussion and voting on the protocol with which the IBC Member has a conflict.

3. Approval of minutes from the previous meeting

The Committee approved the minutes as written from the January 13, 2026, IBC meeting.

Approved (17 voted to approve, 0 opposed, 0 abstained)

4. Review of Approved Protocols- The spreadsheet of FY2026 approved protocols will be sent out for review in April 2026.

5. Old Business –

6. Educational Items – None

7. Occupational Medicine- As of February 1, 2026, there were nine cases of needlesticks, four of which were by students, and five by UT staff. There were three cases of bloodborne exposure: one by a student and two by UT staff members. There was an animal scratch by an LAR staff member. There was an exposure to B

virus by an LAR staff member.

8. Other – None

9. Review of EHS Assistant-

Review any issues with the EH&S Assistant program.

10. Meeting Reminder

The next meeting will be held on March 17, 2026.

Protocols for Review

11. Presentation, Discussion, and Voting on a Renewal Protocol:

Protocol ID: 0000021417

Principal Investigator: Zhang, Nu; Microbiology, Immunology & Molecular Genetics

Title: N/A

Review Type: Full Committee Review

Form Type: Renewal

Approved (17 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with Influenza A, Lymphocytic choriomeningitis virus, and *Listeria monocytogenes* at BSL-2 containment. Work with *E. coli* DH5alpha, Sleeping Beauty transposon system, KPCY cell lines, and vectors (PT3-EF1a-c-MYC, pT3-EF1a-hMET, pT3-ET1a-N90-bCAT, pCMV-SB, pTC-CreERT2-CMV-Tet) at BSL-1 containment.

In vivo

Work with Sleeping Beauty transposon system in knock-out and transgenic mice at ABSL-1 containment.
IACUC# 20150014AR, 20180053AR

In vivo

Work with Influenza A, Lymphocytic choriomeningitis virus, and *Listeria monocytogenes* in knock-out and transgenic mice at ABSL-2 containment.

IACUC# 20150014AR, 20180053AR

Protocol does include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:

Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1

Use of or the cloning of genes from, or into a Risk Group 2, 3, 4 or restricted agent. III-D-1, 2

Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1

Administration of recombinant or synthetic nucleic acid molecules into animals (e.g. transformed cells, vectors) III-D-4

Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3

Experiments involving transgenic/knockout animals requiring ABSL-2 and above containment. III-D-4

12. Presentation, Discussion, and Voting on an Amendment Protocol:**Protocol ID:** 0000021089**Principal Investigator:** Alderete, Joseph; Orthopedics**Title:** N/A**Review Type:** Full Committee Review**Form Type:** Amendment**Approved** (17 voted to approve, 0 opposed, 0 abstained)

Amendment application to work with Methicillin-Susceptible Staphylococcus aureus (MSSA) at BSL-2 containment.

In vivo

Work with Methicillin-Susceptible Staphylococcus aureus (MSSA) in pigs at ABSL-2 containment.

IACUC# IPROTO202500000094

Protocol does not include the use of recombinant DNA.

This protocol was approved with a recommendation.

1. The committee requested additional PPE for lab personnel when wound debridement is performed.

NIH Guidelines:

Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

13. Presentation, Discussion, and Voting on a Renewal Protocol:**Protocol ID:** 0000020889**Principal Investigator:** Bieniek, Kevin; Alzheimer's Neurodegenerative Institute**TITLE:** N/A**Review Type:** Full Committee Review**Form Type:** Renewal**Approved** (17 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with human brain (post mortem), and human blood/tissues/body fluids at BSL-2 containment. Work with Drosophila melanogaster at BSL-1 containment. Work with knock-out mouse strain (P2RY12 cKO) and transgenic mice (APP-SAA, PS19) at ABSL-1 containment.

IACUC # 0220072AP, #IPROTO202500000067

Protocol does not include the use of recombinant DNA


This protocol was approved as written.

*NIH Guidelines:**Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1**Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1**Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3**Experiments involving transgenic/knockout animals requiring ABSL-2 and above containment. III-D-4***14. Presentation, Discussion, and Voting on an Initial Protocol:****Protocol ID:** 0000021244**Principal Investigator:** Li, Hong-Yu; Pharmacology**Title:** N/A**Review Type:** Full Committee Review**Form Type:** Initial**Approved** (17 voted to approve, 0 opposed, 0 abstained)


Initial application to work with human plasma, human microsomes, and human hepatocytes at BSL-2 containment. Work with rat microsomes, rat hepatocytes, and rat plasma at BSL-1 containment.

Protocol does not include the use of recombinant DNA.

This protocol was approved as written.

*NIH Guidelines:**Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1**Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1*Adjourn: The meeting adjourned at 11:43 A.M.

Dr. Yan Xiang
Institutional Biosafety Committee Chair
University of Texas Health San Antonio



Dorothy Macias
Recorder, Institutional Biosafety Committee
University of Texas Health San Antonio

dam